Regencell Bioscience (NASDAQ:RGC) Hits New 52-Week Low – Time to Sell?

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock price reached a new 52-week low during trading on Tuesday . The stock traded as low as $5.60 and last traded at $5.61, with a volume of 565872 shares changing hands. The stock had previously closed at $6.37.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Regencell Bioscience Price Performance

The business has a fifty day moving average of $20.44 and a 200 day moving average of $25.17.

Regencell Bioscience (NASDAQ:RGC) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.00) earnings per share for the quarter.

Institutional Trading of Regencell Bioscience

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Squarepoint Ops LLC acquired a new position in Regencell Bioscience during the second quarter worth $1,701,000. BNP Paribas Financial Markets acquired a new stake in shares of Regencell Bioscience in the second quarter valued at $768,000. XTX Topco Ltd purchased a new stake in shares of Regencell Bioscience in the 3rd quarter valued at $598,000. Bank of America Corp DE raised its holdings in shares of Regencell Bioscience by 59,113.8% in the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after buying an additional 17,143 shares during the period. Finally, Hudson Bay Capital Management LP acquired a new position in Regencell Bioscience during the 4th quarter worth about $275,000. Hedge funds and other institutional investors own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.